AnaptysBio/ US0327241065 /
| 2/3/2023 9:59:59 PM | Chg. -0.81 | Volume | Bid- | Ask- | High | Low |
|---|---|---|---|---|---|---|
| 25.82USD | -3.04% | 6,788 Turnover: 176,515.56 |
-Bid Size: - | -Ask Size: - | 26.88 | 25.75 |
GlobeNewswire
3/14/2022
AnaptysBio Reports Imsidolimab ACORN Phase 2 Clinical Trial Data in Moderate-to-Severe Acne
GlobeNewswire
3/7/2022
AnaptysBio Announces Fourth Quarter and Full Year 2021 Financial Results and Provides Pipeline Updat...
GlobeNewswire
11/15/2021
AnaptysBio Announces Positive Rosnilimab Healthy Volunteer Phase 1 Top-Line Data
GlobeNewswire
11/15/2021
Recludix Pharma Launches with $60 Million Series A to Support Innovative Platform to Discover and De...
GlobeNewswire
11/4/2021
AnaptysBio Announces Third Quarter 2021 Financial Results and Provides Pipeline Updates
GlobeNewswire
10/25/2021
AnaptysBio Announces Agreement to Monetize Portion of JEMPERLI Royalties for $250 Million with Sagar...
GlobeNewswire
10/2/2021
AnaptysBio Presents Updated Data From Imsidolimab Phase 2 GALLOP Trial in Generalized Pustular Psori...
GlobeNewswire
9/9/2021
AnaptysBio to Participate in the H.C. Wainwright 23rd Annual Global Investment Conference
GlobeNewswire
8/17/2021
FDA Grants Accelerated Approval of JEMPERLI (dostarlimab-gxly) for dMMR Recurrent or Advanced Solid ...
GlobeNewswire
8/9/2021
AnaptysBio Announces Second Quarter 2021 Financial Results and Provides Pipeline Updates
GlobeNewswire
8/5/2021
Pardes Biosciences Appoints Deborah M. Autor, J.D. and Laura J. Hamill to Board of Directors
GlobeNewswire
5/4/2021
AnaptysBio Announces First Quarter 2021 Financial Results and Provides Pipeline Updates
GlobeNewswire
4/23/2021
European Commission Approves JEMPERLI (dostarlimab), the First Anti-PD-1 Therapy Approved for Recurr...
GlobeNewswire
3/8/2021
AnaptysBio Reports Imsidolimab POPLAR Phase 2 Clinical Trial in Moderate-to-Severe Palmoplantar Pust...